Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.57 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.56 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | BCHE | P06276 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | ANPEP | P15144 | 1/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22323341 | 0.85 | MEN1 (0.66) | MEN1MAPTKMT2AMTNR1ACHRNB2 | |
| SCHEMBL404391 | 0.84 | MEN1 (0.69) | MEN1MAPTKMT2AMTNR1ACHRNB2 | |
| SCHEMBL1566774 | 0.84 | MEN1 (0.64) | MEN1MAPTKMT2AMTNR1ACHRNB2 | |
| SCHEMBL27548891 | 0.83 | KMT2A (0.59) | MEN1MAPTKMT2AMTNR1ACHRNB2 | |
| SCHEMBL5999001 | 0.82 | NQO2 (0.62) | MEN1MAPTKMT2AMTNR1ACHRNB2 | |
| SCHEMBL1386334 | 0.82 | MEN1 (0.62) | MEN1MAPTKMT2AMTNR1ACHRNB2 | |
| SCHEMBL1386337 | 0.82 | MTNR1A (0.76) | MEN1MAPTKMT2AMTNR1ACHRNB2 | |
| SCHEMBL647494 | 0.81 | MEN1 (0.57) | MEN1MAPTKMT2AMTNR1ACHRNB2 | |
| SCHEMBL4432071 | 0.81 | KMT2A (0.65) | MEN1MAPTKMT2AMTNR1ACHRNB2 | |
| SCHEMBL6565730 | 0.80 | KMT2A (0.56) | MEN1MAPTKMT2AMTNR1ACHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2999338-B1 | KNOWN AND NOVEL HETEROCYCLIC COMPOUNDS AS PESTICIDES | BAYER CROPSCIENCE AG (DE) | 2017-07-12 | — | — | EP | disclosed |
| US-20160106102-A1 | KNOWN AND NEW HETEROCYCLIC COMPOUNDS AS PEST CONTROL AGENTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2016-04-21 | — | — | US | disclosed |
| EP-2999338-A1 | KNOWN AND NEW HETEROCYCLIC COMPOUNDS AS PEST CONTROL AGENTS | Bayer CropScience Aktiengesellschaft (DE) | 2016-03-30 | — | — | EP | disclosed |
| US-7419962-B2 | 3,6-bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-20060142214-A1 | 3,6-bicyclolides | ENANTA PHARMACEUTICALS, INC. | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160106102-A1 | KNOWN AND NEW HETEROCYCLIC COMPOUNDS AS PEST CONTROL AGENTS | DDT, ACHE, NISCH | MEN1 2294/4885MAPT 4125/4885KMT2A 831/4885 |
| US-20060142214-A1 | 3,6-bicyclolides | ABCB11, CYP2B6, CYP3A7 | MEN1 3212/4885MAPT 3856/4885KMT2A 4544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.